Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007088 | Liver | HCC | regulation of mitotic nuclear division | 63/7958 | 110/18723 | 1.24e-03 | 6.85e-03 | 63 |
GO:00059781 | Liver | HCC | glycogen biosynthetic process | 29/7958 | 44/18723 | 1.46e-03 | 7.75e-03 | 29 |
GO:00092501 | Liver | HCC | glucan biosynthetic process | 29/7958 | 44/18723 | 1.46e-03 | 7.75e-03 | 29 |
GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
GO:00432551 | Liver | HCC | regulation of carbohydrate biosynthetic process | 56/7958 | 97/18723 | 1.75e-03 | 9.11e-03 | 56 |
GO:00061122 | Liver | HCC | energy reserve metabolic process | 49/7958 | 84/18723 | 2.46e-03 | 1.19e-02 | 49 |
GO:015010411 | Liver | HCC | transport across blood-brain barrier | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
GO:001023211 | Liver | HCC | vascular transport | 50/7958 | 88/18723 | 4.69e-03 | 2.02e-02 | 50 |
GO:00432444 | Liver | HCC | regulation of protein-containing complex disassembly | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
GO:00321471 | Liver | HCC | activation of protein kinase activity | 72/7958 | 134/18723 | 5.61e-03 | 2.33e-02 | 72 |
GO:004825921 | Liver | HCC | regulation of receptor-mediated endocytosis | 60/7958 | 110/18723 | 7.12e-03 | 2.84e-02 | 60 |
GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
GO:00708732 | Liver | HCC | regulation of glycogen metabolic process | 23/7958 | 36/18723 | 7.85e-03 | 3.11e-02 | 23 |
GO:0032881 | Liver | HCC | regulation of polysaccharide metabolic process | 27/7958 | 44/18723 | 8.98e-03 | 3.46e-02 | 27 |
GO:00346371 | Liver | HCC | cellular carbohydrate biosynthetic process | 44/7958 | 78/18723 | 9.13e-03 | 3.51e-02 | 44 |
GO:001904811 | Liver | HCC | modulation by virus of host process | 9/7958 | 11/18723 | 9.51e-03 | 3.60e-02 | 9 |
GO:004826011 | Liver | HCC | positive regulation of receptor-mediated endocytosis | 31/7958 | 52/18723 | 9.52e-03 | 3.60e-02 | 31 |
GO:0005979 | Liver | HCC | regulation of glycogen biosynthetic process | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
GO:0010962 | Liver | HCC | regulation of glucan biosynthetic process | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
GO:0032885 | Liver | HCC | regulation of polysaccharide biosynthetic process | 23/7958 | 37/18723 | 1.25e-02 | 4.53e-02 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INSR | SNV | Missense_Mutation | | c.3652N>C | p.Asp1218His | p.D1218H | P06213 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.3556N>C | p.Glu1186Gln | p.E1186Q | P06213 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.2585N>C | p.Phe862Ser | p.F862S | P06213 | protein_coding | tolerated(0.88) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.1889N>T | p.Ser630Leu | p.S630L | P06213 | protein_coding | deleterious(0.01) | possibly_damaging(0.459) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.487N>G | p.Ile163Val | p.I163V | P06213 | protein_coding | tolerated(0.06) | benign(0.123) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
INSR | SNV | Missense_Mutation | | c.2072C>G | p.Ser691Cys | p.S691C | P06213 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
INSR | insertion | In_Frame_Ins | novel | c.2752_2753insTGGCACAATCTCAGCTCACTGTAGCCTCCGCCTCCCGGGTTCAAG | p.Pro918delinsLeuAlaGlnSerGlnLeuThrValAlaSerAlaSerArgValGlnAla | p.P918delinsLAQSQLTVASASRVQA | P06213 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1227_1228insAGAAAATGTATTGA | p.Leu412CysfsTer8 | p.L412Cfs*8 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1226_1227insGGGAAGTGACTGCCAAGTTGAAGTTAGGAGTG | p.Phe409LeufsTer17 | p.F409Lfs*17 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | deletion | Frame_Shift_Del | novel | c.2222delN | p.Phe741SerfsTer30 | p.F741Sfs*30 | P06213 | protein_coding | | | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Metformin glycinate | | 22974412 |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201644 | INSULIN ZINC SUSP RECOMBINANT HUMAN | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201638 | INSULIN SUSP PROTAMINE ZINC PURIFIED PORK | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201639 | INSULIN ZINC SUSP BEEF | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201496 | INSULIN ASPART | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | BMS-754807 | BMS-754807 | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | CENISERTIB | CENISERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Insulin-lispro | | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | AEW-541 | AEW-541 | |